香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司股 東減持股份結果公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年3月3日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 股东持股的基本情况 上海昊海生物科技股份有限公司（以下简称"公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期以集中競價交易方式回購公司A股股份的進展公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年3月3日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-005 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/17 | | --- | --- | | 回购方案实施期限 | 自第五届董事会第二十五次会议审议通过后 12 个 | | | 月 | | 预计回购金额 | 10,000.00 万元~20,000.00 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 662,517 股 | | 累计已回购股数占总股本比例 | 0.28% | | 累计已回购金额 | 4,053.64 万元 | | 实际回购价格区间 | 56.78 元/股~63.58 元/股 | 一、 回购股份的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）于 2024 年 ...

上海昊海生物科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688366 证券简称：昊海生科 公告编号：2025-006 重要内容提示： 股东持股的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）股东楼国梁先生于本 次减持计划实施前持有公司无限售条件流通股股份为 8,611,661 股，占减持计划 披露时公司总股本 234,190,295 股的 3.68%。其中，首次公开发行前股份已于 2020 年 10 月 30 日解除限售并上市流通，资本公积金转增股本取得的股份于 2024 年 6 月 20 日上市流通。 减持计划的实施结果情况 公司于 2024 年 11 月 30 日披露了《上海昊海生物科技股份有限公司股东减 持股份计划公告》（公告编号：2024-068），楼国梁先生因自身资金需要，计划自 该公告披露之日起 3 个交易日后 3 个月内，通过集中竞价和大宗交易方式合计减 持不超过 800,000 股的公司股份，占减持计划披露时公司总股本 234,1 ...

Investment Rating - The report gives a "Recommended" rating for the company, Haohai Biological Technology [1]. Core Viewpoints - Haohai Biological Technology is a leading innovator in biomedicine materials, focusing on medical aesthetics and artificial crystalline lenses as its main growth drivers [10][15]. - The company has shown significant revenue growth in its core products, particularly hyaluronic acid and artificial crystalline lenses, with a projected increase in net profit for the coming years [5][17]. - The medical aesthetics sector is identified as a second growth curve for the company, with a strong market presence and potential for further market share expansion [25][29]. Summary by Sections Company Overview - Haohai Biological Technology, established in 2007, specializes in the research, production, and sales of medical biopolymer materials, covering fields such as ophthalmology, medical aesthetics, wound care, orthopedics, and surgery [10][15]. - The company is a major supplier of artificial crystalline lenses in China, with a stable and concentrated shareholding structure [12][15]. Financial Performance - The company reported a revenue of 2,130 million yuan in 2022, with a projected increase to 3,468 million yuan by 2026, reflecting a compound annual growth rate [5]. - In 2023, the company achieved a net profit of 4.2 billion yuan, a significant increase of 130.6% year-on-year, driven by stable production and sales recovery [17][18]. Product Analysis - The main products include hyaluronic acid and artificial crystalline lenses, with 2023 revenues of 6.0 billion yuan (+95.5%) and 3.8 billion yuan (+37%), respectively [7][15]. - The company has a diverse product matrix in hyaluronic acid, with three main products: Haiwei, Jiaolan, and Haimei, catering to different market segments [29][33]. Market Potential - The artificial crystalline lens market is expected to grow due to an aging population and increasing demand for cataract surgeries, with the market size reaching 25.5 billion yuan in 2022 [38][41]. - The report highlights the potential for domestic brands to capture market share from imported high-end products, particularly in the context of national procurement policies [43][45]. Competitive Landscape - The report compares Haohai Biological Technology with peers such as Aibo Medical and Huaxi Biological, suggesting an average valuation of 28 times for comparable companies [7][54]. - The company is positioned to benefit from ongoing trends in the medical aesthetics market, with a focus on innovation and product development [28][29].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company achieved a revenue of 2.698 billion yuan in 2024, reflecting a year-on-year growth of 1.64%, while the net profit attributable to shareholders was 420 million yuan, up 0.97% year-on-year [1][2] - The decline in Q4 revenue is attributed to the price drop from centralized procurement of artificial crystals, but the company is expected to see long-term growth supported by the high-end hyaluronic acid product "Hai Mei Yue Bai" [1][2] - The company is continuously enhancing its aesthetic medicine marketing team, with a focus on expanding the sales team for its hyaluronic acid products, which have shown strong market performance [2][3] Financial Performance - Revenue projections for 2024-2026 are 2.698 billion, 3.131 billion, and 3.637 billion yuan, with year-on-year growth rates of 1.6%, 16.1%, and 16.2% respectively [3][4] - Net profit forecasts for the same period are 420 million, 521 million, and 660 million yuan, with growth rates of 0.8%, 24.1%, and 26.7% respectively [3][4] - The company’s P/E ratios are projected to be 32.8, 26.5, and 20.9 for 2024, 2025, and 2026 respectively [4] Product Development - The company is actively investing in new product development, with a comprehensive product matrix in aesthetic medicine that includes botulinum toxin, hyaluronic acid, and hydroxyapatite [3] - The fourth-generation hyaluronic acid product "Hai Mei Yue Bai" was approved in July 2024, expected to enhance market competitiveness due to its superior safety and efficacy [2][3]

Investment Rating - The report maintains a "Buy" rating for Haohai Biological Technology (688366.SH) [5] Core Views - The company achieved a revenue of 2.698 billion yuan in 2024, reflecting a year-on-year growth of 1.64%. The net profit attributable to shareholders was 420 million yuan, with a slight increase of 0.97%. However, the net profit after deducting non-recurring items decreased by 0.57% to 381 million yuan [1][2] - The decline in revenue growth in Q4 2024 is attributed to the price drop from the centralized procurement of artificial crystals. Despite this, the company is expected to see long-term growth supported by the high-end hyaluronic acid product "Haimei Yuebai" [1][2] - The company is actively enhancing its aesthetic medicine marketing team, with plans to expand the sales team further. The product mix for hyaluronic acid has been differentiated in terms of functionality and pricing, which is expected to drive growth [2][3] Financial Performance Summary - For 2024, the company reported a revenue of 2.698 billion yuan, with projected revenues of 3.131 billion yuan and 3.637 billion yuan for 2025 and 2026, respectively, indicating growth rates of 16.1% and 16.2% [3][4] - The net profit for 2024 is projected to be 421 million yuan, with expected growth rates of 24.1% and 26.7% for 2025 and 2026 [3][4] - The report provides a detailed financial outlook, including earnings per share (EPS) estimates of 1.80 yuan for 2024, increasing to 2.83 yuan by 2026 [4][3] Product Development and Market Position - The company is focusing on new product development across its aesthetic medicine product line, which includes botulinum toxin, hyaluronic acid, and hydroxyapatite. The product matrix is becoming increasingly comprehensive [3] - The fourth-generation hyaluronic acid product "Haimei Yuebai" was approved in July 2024, which is expected to enhance market competitiveness and drive future sales [2][3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2024年度業績快報公告 上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 《證券及期貨條例》（香港法例第571章）第XIVA部及《香港聯合交易所有限公司證 券上市規則》第13.09及13.10B條的要求發佈本公告，旨在向本公司股東及公眾人 士提供本公司的財務資料。本公告亦同時在上海證券交易所網站發佈。 本公告所載本集團按照中國企業會計準則編製的截至2024年12月31日止年度（「報 告期」）主要財務數據為初步核算未經核數師審計的數據。本集團報告期的具體財 務數據及經營業績將以本公司截至2024年12月31日止年度經審核之業績公告及本 公司2024年度報告所披露者為準。提請本公司潛在 ...

Financial Performance - Total revenue for 2024 reached RMB 269,765.79 million, a year-on-year increase of 1.64%[4] - Net profit attributable to shareholders was RMB 42,015.41 million, reflecting a growth of 0.97% compared to the previous year[4] - Basic earnings per share rose to RMB 1.80, up 2.86% from RMB 1.75 in the previous year[4] - The net profit excluding non-recurring gains and losses was RMB 38,120.90 million, a slight decrease of 0.57% year-on-year[4] - The weighted average return on net assets was 7.41%, an increase of 0.02 percentage points from the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were RMB 712,469.06 million, an increase of 0.27% from the beginning of the period[7] - The equity attributable to shareholders decreased by 1.20% to RMB 558,244.99 million[7] - The company's share capital increased by 35.99% to RMB 23,319.37 million due to the issuance of 66,782,692 new shares in June 2024[8] Operational Strategy - The company focused on optimizing product structure and enhancing operational efficiency to improve profitability[7] Audit and Reporting - The financial data presented is preliminary and subject to final audit in the annual report[9]

证券代码：688366 证券简称：昊海生科 公告编号：2025-003 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/17 | | --- | --- | | 回购方案实施期限 | 自第五届董事会第二十五次会议审议通过后 12 个 | | | 月 | | 预计回购金额 | 10,000.00 万元~20,000.00 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 662,517 股 | | 累计已回购股数占总股本比例 | 0.28% | | 累计已回购金额 | 4,053.64 万元 | | 实际回购价格区间 | 56.78 元/股~63.58 元/股 | 2025 年 1 月，公司通过集中竞价交易方式已累计回购公司 A 股股份 169,771 股 ...